CRANBURY - Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today.
Financialnewsmedia.com: Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.